表紙
市場調查報告書

腦病變:開發中產品分析

Encephalopathy - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 362373
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
腦病變:開發中產品分析 Encephalopathy - Pipeline Review, H2 2019
出版日期: 2019年12月05日內容資訊: 英文 69 Pages
簡介

本報告提供腦病變治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

腦病變概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腦病變:企業開發中的治療藥

腦病變:大學/機關研究中的治療藥

腦病變:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

腦病變:企業開發中的產品

腦病變:大學/機關研究中的產品

腦病變的治療藥的開發企業

  • Amarantus Bioscience Holdings, Inc.
  • Celgene Corporation
  • Chiesi Farmaceutici SpA
  • Fera Pharmaceuticals, LLC
  • GW Pharmaceuticals Plc
  • JS Genetics Inc.
  • KannaLife Sciences, Inc.
  • ProThera Biologics, LLC.
  • SciFluor Life Sciences, LLC
  • Turing Pharmaceuticals AG
  • Versantis
  • Zambon Company S.p.A.

腦病變:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腦病變:最近的開發平台趨勢

腦病變:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11603IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Pipeline Review, H2 2019, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 2, 2, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Encephalopathy - Overview
  • Encephalopathy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Encephalopathy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Encephalopathy - Companies Involved in Therapeutics Development
  • BrainRepair UG
  • Celularity Inc
  • GW Pharmaceuticals Plc
  • Hope Biosciences LLC
  • Inflazome Ltd
  • JS Genetics Inc
  • Mesoblast Ltd
  • Mithra Pharmaceuticals SA
  • Orphan Star Therapeutics LLC
  • Pfizer Inc
  • ProThera Biologics Inc
  • ReAlta Life Sciences Inc
  • SL Bigen Inc
  • Worphmed Srl
  • Encephalopathy - Drug Profiles
  • Alda-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • diazoxide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Target SLC2A1 for Glut1 Deficiency Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • estetrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GWP-42003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MCC-950 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • melatonin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Inhibit IL-2 for Encephalopathy, Graft Versus Host Disease and Type 1 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Target Complement C1q for Acute Intravascular Hemolytic Transfusion and Hypoxic-ischemic Encephalopathy Reaction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Target Complement C1q for Hypoxic-ischemic Encephalopathy, Infectious Diseases and Systemic Lupus Erythematosus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PSC-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remestemcel-L - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SLBM-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Encephalopathy - Dormant Projects
  • Encephalopathy - Discontinued Products
  • Encephalopathy - Product Development Milestones
  • Featured News & Press Releases
  • Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
  • Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
  • Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy
  • Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
  • Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Encephalopathy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Encephalopathy - Pipeline by BrainRepair UG, H2 2019
  • Encephalopathy - Pipeline by Celularity Inc, H2 2019
  • Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H2 2019
  • Encephalopathy - Pipeline by Hope Biosciences LLC, H2 2019
  • Encephalopathy - Pipeline by Inflazome Ltd, H2 2019
  • Encephalopathy - Pipeline by JS Genetics Inc, H2 2019
  • Encephalopathy - Pipeline by Mesoblast Ltd, H2 2019
  • Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, H2 2019
  • Encephalopathy - Pipeline by Orphan Star Therapeutics LLC, H2 2019
  • Encephalopathy - Pipeline by Pfizer Inc, H2 2019
  • Encephalopathy - Pipeline by ProThera Biologics Inc, H2 2019
  • Encephalopathy - Pipeline by ReAlta Life Sciences Inc, H2 2019
  • Encephalopathy - Pipeline by SL Bigen Inc, H2 2019
  • Encephalopathy - Pipeline by Worphmed Srl, H2 2019
  • Encephalopathy - Dormant Projects, H2 2019
  • Encephalopathy - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Encephalopathy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top